莫沙必利治疗114例胃食管反流病临床观察

目的:评价莫沙必利治疗胃食管反流病(GERD)的作用及安全性。方法:采用随机对照临床研究的方法,将诊断为GERD的114例患者随机分为3组,奥美拉唑+莫沙必利组36例,奥美拉唑+吗丁啉组38例,单纯奥美拉唑组40例,疗程为4周。结果:治疗2周时自觉症状的缓解率在3组之间差异无统计学意义,但奥美拉唑+莫沙必利组治疗4周时的症状缓解率明显优于单纯奥美拉唑组(P<0.05),而且在停药2周后症状的复发率也明显低于单纯奥美拉唑组(P<0.05),但与奥美啦唑+吗丁啉组比较差异无统计学意义。治疗4周后监测食管下段24hpH值,结果表明,接受奥美拉唑+莫沙必利治疗者pH值<4时间百分比(pH值<4时间%)和持续≥5min的反流次数比奥美拉唑+吗丁啉组和单纯奥美拉唑组明显减少(P<0.05),但pH值<4的反流次数及下食管括约肌压力(LESP)在3组间差异无统计学意义。结论:口服莫沙必利可以明显减少食管下段pH值<4时间%及长时间反流次数,并可有效的缓解GERD的症状,且复发率较单纯应用奥美拉唑治疗明显降低。

Clinical observation of Mosapride in the treatment of gastroesophageal reflux disease:A report of 114 cases

Objective To evaluate the utility and safety of Mosapride in curing gastroesophageal reflux disease(GERD).Method According to the clinical study method of random comparison,114 patients were departed into three groups at random(36 for Omeprazole and Mosapride,38 for Omeprazole and Domperidone and 40 for only Omeprazole).The course of treatment lasted four weeks.Results After two weeks' treating,there was no significant difference in the remission rate of the rational symptom of the three.But after four week...